SAGE Therapeutics Inc (SAGE) was Initiated by Chardan Capital Markets to “Sell” and the brokerage firm has set the Price Target at $18. Chardan Capital Markets advised their investors in a research report released on May 24, 2016.
Many Wall Street Analysts have commented on SAGE Therapeutics Inc. SAGE Therapeutics Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016. Lake Street Initiated SAGE Therapeutics Inc on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $90.
SAGE Therapeutics Inc opened for trading at $30.41 and hit $32.055 on the upside on Friday, eventually ending the session at $31.21, with a gain of 3.07% or 0.93 points. The heightened volatility saw the trading volume jump to 8,26,110 shares. Company has a market cap of $1,000,717 M.
In a different news, on Apr 21, 2016, Stephen Kanes (Chief Medical Officer) sold 21,000 shares at $38.00 per share price. According to the SEC, on Jan 7, 2016, Kimi Iguchi (CFO) purchased 176 shares at $49.56 per share price. On Aug 4, 2015, Albert Robichaud (Chief Scientific Officer) sold 12,000 shares at $67.06 per share price, according to the Form-4 filing with the securities and exchange commission.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.